Search

Your search keyword '"Aerts, I."' showing total 280 results
Start Over Author "Aerts, I."
280 results on '"Aerts, I."'

1. Retinoblastoma: From genes to patient care

Author

Bouchoucha, Y., Matet, A., Berger, A., Carcaboso, A.M., Gerrish, A., Moll, A., Jenkinson, H., Ketteler, P., Dorsman, J.C., Chantada, G., Beck-Popovic, M., Munier, F., Aerts, I., Doz, F., and Golmard, L.

Published
2023
Full Text
View/download PDF

3. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆

Author

Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., Morland, B., Rossig, C., Canete Nieto, A., Longhi, A., Lervat, C., Entz-Werle, N., Strauss, S.J., Marec-Berard, P., Okpara, C.E., He, C., Dutta, L., and Casanova, M.

Published
2021
Full Text
View/download PDF

4. Retinoblastoma

Author

Aerts, I., Lumbroso-Le Rouic, L., Gauthier-Villars, M., Brisse, H.-J., Fréneaux, P., and Doz, F.

Published
2021
Full Text
View/download PDF

6. 59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts

Author

Dufresne, A., Brahmi, M., Cropet, C., Bahleda, R., Watson, S., Pautier, P., Ray-Coquard, I.L., Aerts, I., Duffaud, F., Defachelles, A-S., Verret, B., Garin, G. Fournier, Guichard, C., Bernardin, M., Perol, D., Blay, J-Y., and Corradini, N.

Published
2024
Full Text
View/download PDF

11. Retinoblastoma

Author

Aerts, I., Lumbroso-Le Rouic, L., Gauthier-Villars, M., Brisse, H.-J., Sastre-Garau, X., and Doz, F.

Published
2014
Full Text
View/download PDF

12. 468P Real-world safety of trametinib monotherapy or in combination with dabrafenib in children, adolescents, and young adults with relapsed or refractory low-grade glioma (LGG) and high-grade glioma (HGG)

Author

Taleb, N., Ndounga-Diakou, L.A., Abbou, S., Leblond, P., Aerts, I., Sevrin, F., Ducassou, S., André, N., Entz-Werle, N., Chastagner, P., Plantaz, D., Gambart, M., Puiseux, C., Khanfar, C., Thouvenin, S., Schneider, P., Vassal, G., Berlanga, P., and Laghouati, S.

Published
2024
Full Text
View/download PDF

13. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies

Author

Illiano, M., primary, Colinard, M., additional, Taque, S., additional, Mallon, B., additional, Larue, C., additional, Laithier, V., additional, Vérité-Goulard, C., additional, Sudour-Bonnange, H., additional, Faure-Conter, C., additional, Coze, C., additional, Aerts, I., additional, De Maricourt, C. Dumesnil, additional, Paillard, C., additional, Branchereau, S., additional, Brugières, L., additional, and Fresneau, B., additional

Published
2021
Full Text
View/download PDF

16. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Author

Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, Franco, Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., Aerts, I., Strauss, S. J., Thebaud, E., Morland, B., Nieto, A. C., Marec-Berard, P., Gambart, M., Rossig, C., Okpara, C. E., He, C., Dutta, L., Campbell-Hewson, Q., Locatelli F. (ORCID:0000-0002-7976-3654), Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, Franco, Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., Aerts, I., Strauss, S. J., Thebaud, E., Morland, B., Nieto, A. C., Marec-Berard, P., Gambart, M., Rossig, C., Okpara, C. E., He, C., Dutta, L., Campbell-Hewson, Q., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Background: Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma. Methods: This multicentre, open-label, multicohort, phase 1/2 trial was done at 17 hospitals in six countries. Eligible patients were aged 2–25 years, had relapsed or refractory osteosarcoma, measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1, Lansky play–performance score or Karnofsky performance score of 50% or higher, up to one previous VEGF or VEGF receptor-targeted therapy, and a life expectancy of at least 3 months. This study includes a combination dose-finding phase 1 part (cohort 3A) and a phase 2 combination expansion in patients with osteosarcoma (cohort 3B). Lenvatinib was administered orally at a starting dose of 11 mg/m2 per day, capped at 24 mg per day, and etoposide (100 mg/m2 per day) plus ifosfamide (3000 mg/m2 per day) were administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. Lenvatinib monotherapy continued after these five cycles until disease progression, toxic effects, or patient choice to discontinue. The phase 1 primary endpoint was to determine the recommended phase 2 dose by evaluating dose-limiting toxicity and the phase 2 primary endpoint was progression-free survival at 4 months. Progression-free survival was measured in the full analysis set, which included all patients enrolled for efficacy outcomes; safety was assessed in all patients who received any study drug. This study is registered with ClinicalTrials.gov, NCT02432274. Findings: 30 patients were screened for enrolment into cohort 3A between May 9, 2016, and June 3, 2019, and 22 patients for enrolment into cohort 3B between Sept 13, 2018, and July 18, 2019. Eight patients from cohort 3A and two from cohort 3B

Published
2021

17. Le rétinoblastome

Author

Aerts, I., Lumbroso-Le Rouic, L., Gauthier-Villars, M., Brisse, H., Levy-Gabriel, C., Doz, F., and Desjardins, L.

Published
2006
Full Text
View/download PDF

18. Malformations, Genetic Abnormalities, and Wilms Tumor

Author

Dumoucel, S., Gauthier-Villars, M., Stoppa-Lyonnet, D., Parisot, P., Brisse, H., Philippe-Chomette, P., Sarnacki, S., Boccon-Gibod, L., Rossignol, S., Baumann, C., Aerts, I., Bourdeaut, F., Doz, F., Orbach, D., Pacquement, H., Michon, J., and Schleiermacher, G.

Published
2014
Full Text
View/download PDF

22. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium

Author

Rubio-San-Simon, A., Andre, N., Cefalo, M. G., Aerts, I., Castaneda, A., Benezech, S., Makin, G., van Eijkelenburg, N., Nysom, K., Marshall, L., Gambart, M., Hladun, R., Rossig, C., Bergamaschi, L., Fagioli, F., Carpenter, B., Ducassou, S., Owens, C., Ora, I., Ribelles, A. J., De Wilde, B., Guerra-Garcia, P., Strullu, M., Rizzari, C., Ek, T., Hettmer, S., Gerber, N. U., Rawlings, C., Diezi, M., Palmu, S., Ruggiero, Antonio, Verdu, J., de Rojas, T., Vassal, G., Geoerger, B., Moreno, L., Bautista, F., Ruggiero A. (ORCID:0000-0002-6052-3511), Rubio-San-Simon, A., Andre, N., Cefalo, M. G., Aerts, I., Castaneda, A., Benezech, S., Makin, G., van Eijkelenburg, N., Nysom, K., Marshall, L., Gambart, M., Hladun, R., Rossig, C., Bergamaschi, L., Fagioli, F., Carpenter, B., Ducassou, S., Owens, C., Ora, I., Ribelles, A. J., De Wilde, B., Guerra-Garcia, P., Strullu, M., Rizzari, C., Ek, T., Hettmer, S., Gerber, N. U., Rawlings, C., Diezi, M., Palmu, S., Ruggiero, Antonio, Verdu, J., de Rojas, T., Vassal, G., Geoerger, B., Moreno, L., Bautista, F., and Ruggiero A. (ORCID:0000-0002-6052-3511)

Abstract

Introduction: Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I–II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). Methods: A survey was sent to all ITCC-accredited early-phase clinical trial hospitals including questions about impact on staff activities, recruitment, patient care, supply of investigational products and legal aspects, between 1st March and 30th April 2020. Results: Thirty-one of 53 hospitals from 12 countries participated. Challenges reported included staff constraints (30% drop), reduction in planned monitoring activity (67% drop of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop compared with that in 2019). The percentage of phase I, phase II trials and molecular platforms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively. In addition, 26% of sites had restrictions on performing trial assessments because of local contingency plans. Almost half of the units suffered impact upon pending contracts. Most hospitals (65%) are planning on improving organisational and structural changes. Conclusion: The study reveals a profound disruption of paediatric cancer early-phase clinical research due to the COVID-19 pandemic across Europe. Reported difficulties affected both patient care and monitoring activity. Efforts should be made to reallocate resources to avoid lost opportunities for patients and to allow the continued advancement of oncology research. Identified adaptations to clinical trial procedures may be integrated to increase preparedness of clinical research to futures crises.

Published
2020

23. Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium

Author

Rubio San Simón, A, André, N, Cefalo, M, Aerts, I, Castañeda, A, Benezech, S, Makin, G, van Eijkelenburg, N, Nysom, K, Marshall, L, Gambart, M, Hladun, R, Rossig, C, Bergamaschi, L, Fagioli, F, Carpenter, B, Ducassou, S, Owens, C, Øra, I, Ribelles, A, De Wilde, B, Guerra García, P, Strullu, M, Rizzari, C, Ek, T, Hettmer, S, Gerber, N, Rawlings, C, Diezi, M, Palmu, S, Ruggiero, A, Verdú, J, de Rojas, T, Vassal, G, Geoerger, B, Moreno, L, Bautista, F, Cefalo, MG, van Eijkelenburg N, Ribelles, AJ, Rubio San Simón, A, André, N, Cefalo, M, Aerts, I, Castañeda, A, Benezech, S, Makin, G, van Eijkelenburg, N, Nysom, K, Marshall, L, Gambart, M, Hladun, R, Rossig, C, Bergamaschi, L, Fagioli, F, Carpenter, B, Ducassou, S, Owens, C, Øra, I, Ribelles, A, De Wilde, B, Guerra García, P, Strullu, M, Rizzari, C, Ek, T, Hettmer, S, Gerber, N, Rawlings, C, Diezi, M, Palmu, S, Ruggiero, A, Verdú, J, de Rojas, T, Vassal, G, Geoerger, B, Moreno, L, Bautista, F, Cefalo, MG, van Eijkelenburg N, and Ribelles, AJ

Abstract

Introduction: Data regarding real-world impact on cancer clinical research during COVID-19 are scarce. We analysed the impact of the COVID-19 pandemic on the conduct of paediatric cancer phase I–II trials in Europe through the experience of the Innovative Therapies for Children with Cancer (ITCC). Methods: A survey was sent to all ITCC-accredited early-phase clinical trial hospitals including questions about impact on staff activities, recruitment, patient care, supply of investigational products and legal aspects, between 1st March and 30th April 2020. Results: Thirty-one of 53 hospitals from 12 countries participated. Challenges reported included staff constraints (30% drop), reduction in planned monitoring activity (67% drop of site initiation visits and 64% of monitoring visits) and patient recruitment (61% drop compared with that in 2019). The percentage of phase I, phase II trials and molecular platforms closing to recruitment in at least one site was 48.5%, 61.3% and 64.3%, respectively. In addition, 26% of sites had restrictions on performing trial assessments because of local contingency plans. Almost half of the units suffered impact upon pending contracts. Most hospitals (65%) are planning on improving organisational and structural changes. Conclusion: The study reveals a profound disruption of paediatric cancer early-phase clinical research due to the COVID-19 pandemic across Europe. Reported difficulties affected both patient care and monitoring activity. Efforts should be made to reallocate resources to avoid lost opportunities for patients and to allow the continued advancement of oncology research. Identified adaptations to clinical trial procedures may be integrated to increase preparedness of clinical research to futures crises.

Published
2020

25. Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma

Author

Gaspar, N., primary, Sirvent, F J Bautista, additional, Venkatramani, R., additional, Longhi, A., additional, Lervat, C., additional, Casanova, M., additional, Aerts, I., additional, Bielack, S.S., additional, Entz-Werle, N., additional, Strauss, S., additional, He, C., additional, Thebaud, E., additional, Locatelli, F., additional, Morland, B., additional, Melcon, S Gallego, additional, Nieto, A Cañete, additional, Marec- Bérard, P., additional, Gambart, M., additional, Rossig, C., additional, and Campbell-Hewson, Q., additional

Published
2019
Full Text
View/download PDF

26. Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines

Author

la Monneraye, Yvan, primary, Michon, J., additional, Pacquement, H., additional, Aerts, I., additional, Orbach, Daniel., additional, Doz, F., additional, Bourdeaut, F., additional, Sarnacki, S., additional, Philippe‐Chomette, P., additional, Audry, G., additional, Coulomb, A., additional, Fréneaux, P., additional, Klijanienko, J., additional, Berrebi, D., additional, Zucker, J.‐M., additional, Schleiermacher, G., additional, and Brisse, H.J., additional

Published
2019
Full Text
View/download PDF

28. Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours

Author

Nysom, K., primary, Leblond, P., additional, Frappaz, D., additional, Aerts, I., additional, Varlet, P., additional, Giangaspero, F., additional, Gambart, M., additional, Hargrave, D., additional, Marshall, L., additional, Kearns, P., additional, Makin, G., additional, Gallego, S., additional, Kieran, M., additional, Casanova, M., additional, Lahogue, A., additional, Wind, S., additional, Stolze, B., additional, Roy, D., additional, Uttenreuther-Fischer, M., additional, and Geoerger, B., additional

Published
2017
Full Text
View/download PDF

29. 1676PD - Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma

Author

Gaspar, N., Sirvent, F J Bautista, Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S.S., Entz-Werle, N., Strauss, S., He, C., Thebaud, E., Locatelli, F., Morland, B., Melcon, S Gallego, Nieto, A Cañete, Marec- Bérard, P., Gambart, M., Rossig, C., and Campbell-Hewson, Q.

Published
2019
Full Text
View/download PDF

30. New challenges in retinoblastoma treatment

Author

Desjardins, L., primary, Angi, M., additional, Levy, C., additional, Lumbroso Le Rouic, L., additional, Aerts, I., additional, Freneaux, P., additional, Brisse, H., additional, and Cassoux, N., additional

Published
2016
Full Text
View/download PDF

31. Cranio-facial second primary tumors in retinoblastoma patients previously treated by radiation therapy : a multicenter clinical and radiological study of 42 patients

Author

de Graaf, P., Rodjan, F., Brisse, H. J., Verbeke, JILM, Sanchez, E., Galluzzi, P., Göricke, Sophia Luise, Maeder, P., Aerts, I., Dendale, R., Desjardins, L., de Franscesco, S., Bornveld, N., Sauerwein, Wolfgang, Popovic, M. B., Knol, D. L., Moll, A. C., and Castelijns, J. A.

Subjects
Medizin
Abstract

Poster-Abstract

Published
2012

32. Comment les parents perçoivent-ils la prise en charge de leur enfant atteint de rétinoblastome ?

Author

Delage, M., Boisserolles, V., Savignioni, A., Desjardins, L., Aerts, I., Gauthier-Villars, M., Lumbroso, L., Levy, C., Estève, M., Asselain, B., Doz, F., and Seigneur, E.

Abstract

Le rétinoblastome est un cancer rare qui touche principalement les nourrissons et les jeunes enfants et qui implique l’œil, organe dont la valeur symbolique est grande. En raison de la brutalité du diagnostic, de l’âge de l’enfant, de l’organe touché, du contexte de prédisposition génétique, possible ou certaine, et de la blessure narcissique ressentie par les parents, il apparaît important d’évaluer la satisfaction de ces parents vis-à-vis de la prise en charge thérapeutique de leur enfant. Dans cette étude, nous avons mené, au moment du diagnostic et un an plus tard, des entretiens semi-directifs avec les parents auxquels nous avons également remis des questionnaires visant à évaluer leur ressenti. Trente-huit familles ont participé à l’étude, l’âge moyen des enfants traités était de 13 mois. La moitié des enfants présentaient un rétinoblastome bilatéral et, parmi ceux-ci, 76 % avaient subi une énucléation unilatérale. Les résultats montrent que la majorité des parents ont été satisfaits de la prise en charge, en dépit du traumatisme lié au diagnostic et au traitement. Ils mettent en avant l’importance de la disponibilité et de la cohérence des équipes pédiatriques et ophtalmologiques, la totale confiance dans les médecins « spécialistes », même si les informations reçues sont difficiles à intégrer, particulièrement celles concernant les aspects génétiques. Dans un tel contexte, le soutien psychologique apparaît important, tant au moment du diagnostic qu’à l’issue du traitement, pour anticiper l’avenir de l’enfant et son handicap éventuel. Les résultats de cette étude devraient permettre une amélioration de la prise en charge globale des enfants atteints de rétinoblastome.

Published
2024
Full Text
View/download PDF

34. 23 Na MRI longitudinal follow-up of PDT in a xenograft model of human retinoblastoma

Author

Lupu, M., Thomas, C.D., Maillard, Philippe, Loock, Bernard, Chauvin, B., Aerts, I., Croisy, A., Belloir, E., Volk, A., Mispelter, Joël, Conception, synthèse et vectorisation de biomolécules. (CSVB), Institut Curie-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), and Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

35. Cycling to work

Author

de Geus, B, Van Hoof, E, Aerts, I, Meeusen, R, Human Physiology and Special Physiology of Physical Education, Cognitive and Biological Psychology, Faculty of Law and Criminology, Electrical Engineering and Power Electronics, Electrochemical and Surface Engineering, and Vrije Universiteit Brussel

Subjects
Adult, Male, Research Support, Non-U.S. Gov't, health status, Transportation, Middle Aged, coronary disease, Bicycling, Belgium, Journal Article, Humans, Female, Quality Of Life, Aged
Abstract

The purpose of this study was to examine if a 1-year lifestyle intervention study (cycling to work) has an influence on coronary heart disease (CHD) risk factors and health-related quality of life, in previously untrained healthy adults. Healthy, untrained men and women, who did not cycle to work, participated in an intervention study. Sixty-five subjects (intervention group: IG) were asked to cycle to work at least 3 times a week and 15 controls (CG) were asked not to change their living habits. All measurements were performed on 3 consecutive occasions, with 6 months in between. Physical performance, venous blood samples, blood pressure (BP), and the SF-36 Health Status Survey were assessed. Cycling characteristics and leisure-time physical activities were reported in a dairy. Total cholesterol (TC), LDL, TC/HDL and diastolic BP decreased and HDL increased significantly in the IG. TC and LDL decreased significantly in the CG. Vitality for the total group and physical functioning for women significantly changed over time between IG and CG in the first 6 months. These results show that cycling to work has a positive influence on CHD risk factors and is likely to improve the health-related quality of life in previously untrained healthy adults.

Published
2008
Full Text
View/download PDF

37. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.

Author

Geoerger, B, Chisholm, J, Le Deley, Mc, Gentet, Jc, Zwaan, Cm, Dias, N, Jaspan, T, Hugh, K, Couanet, D, Hain, S, Devos, A, Riccardi, Riccardo, Cesare, C, Boos, J, Frappaz, D, Leblond, P, Aerts, I, Vassal, G., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Geoerger, B, Chisholm, J, Le Deley, Mc, Gentet, Jc, Zwaan, Cm, Dias, N, Jaspan, T, Hugh, K, Couanet, D, Hain, S, Devos, A, Riccardi, Riccardo, Cesare, C, Boos, J, Frappaz, D, Leblond, P, Aerts, I, Vassal, G., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)

Abstract

AIM: To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours. METHODS: This multicentre, non-randomised Phase II study included five strata: neuroblastoma, osteosarcoma, medulloblastoma and other CNS tumours strata with two-stage Simon designs and a miscellaneous, extra-cranial solid tumour stratum with descriptive design. Eligibility criteria included: age 6 months to 21 years; measurable, relapsed or refractory solid malignancy; no more than one previous salvage therapy. Gemcitabine was administered intravenously at 1000 mg/m(2) over 100 min followed by oxaliplatin at 100mg/m(2) over 120 min on Day 1 of a 14-d cycle. Tumour response was assessed every 4 cycles according to WHO criteria. RESULTS: Ninety-three out of 95 patients enrolled in 25 centres received treatment: 12 neuroblastoma; 12 osteosarcoma; 14 medulloblastoma; 13 other CNS tumours and 42 miscellaneous non-CNS solid tumours. Median age was 11.7 years (range, 1.3-20.8 years). Tumour control (CR+PR+SD) at 4 cycles was obtained in 30/93 evaluable patients (32.3%; 95% confidence interval (CI), 22.9-42.7%), including four PR: 1/12 patients with osteosarcoma, 1/12 with medulloblastoma, 1/12 with rhabdomyosarcoma and 1/4 with other sarcoma. Five out of 12 eligible patients with neuroblastoma experienced stable disease. During a total of 481 treatment cycles (median 4, range 1-24 per patient), the most common treatment-related toxicities were haematologic (leukopenia, neutropenia, thrombocytopenia) and neurological (dysesthesia, paresthesia). CONCLUDING STATEMENT: The gemcitabine-oxaliplatin combination administered in a bi-weekly schedule has acceptable safety profile with limited activity in children with relapsed or refractory solid tumours.

Published
2011

38. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

Author

Geoerger, B, Hargrave, D, Thomas, F, Ndiaye, A, Frappaz, D, Andreiuolo, F, Varlet, P, Aerts, I, Riccardi, Riccardo, Jaspan, T, Chatelut, E, Le Deley, Mc, Paoletti, X, Saint Rose, C, Leblond, P, Morland, B, Gentet, Jc, Meresse, V, Vassal, G., Riccardi, Riccardo (ORCID:0000-0001-7515-6622), Geoerger, B, Hargrave, D, Thomas, F, Ndiaye, A, Frappaz, D, Andreiuolo, F, Varlet, P, Aerts, I, Riccardi, Riccardo, Jaspan, T, Chatelut, E, Le Deley, Mc, Paoletti, X, Saint Rose, C, Leblond, P, Morland, B, Gentet, Jc, Meresse, V, Vassal, G., and Riccardi, Riccardo (ORCID:0000-0001-7515-6622)

Abstract

This multicenter phase I study aimed to establish the recommended dose (RD) of the epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with radiotherapy to children with malignant brain tumors. Group 1 included patients with refractory or relapsing brain tumors receiving erlotinib alone, and group 2 included newly diagnosed patients with brainstem gliomas receiving radiotherapy and erlotinib. A conventional 3 + 3 dose escalation and a continual reassessment method, respectively, were utilized in 4 dose levels: 75, 100, 125, and 150 mg/m2 per day. Fifty-one children were enrolled (30 and 21, respectively); 50 received treatment. The RD of erlotinib was 125 mg/m2 per day as monotherapy or in combination with radiotherapy. Overall, 230 adverse events in 44 patients were possibly treatment related (216, grades 1 and 2; 9, grade 3; 1, grade 4; 4, grade 5). Dermatologic and neurologic symptoms were common; intratumoral hemorrhage was confirmed in 3 patients. In group 1, 8 of 29 patients (28%) had stable disease with tumor regression approaching 50% in a malignant glioma and an anaplastic oligoastrocytoma. In group 2, overall survival was 12.0 months. EGFR overexpression by immunohistochemistry was found in 17 of 38 (45%) tumor samples analyzed, with a partial gain of 7p11.2 in 1 glioblastoma; phosphate and tensin homolog loss was frequent in brainstem glioma (15 of 19). Mean (95% CI) apparent clearance and volume of distribution for erlotinib were 4.0 L/h (3.4-4.5 L/h) and 98.6 L (69.8-127.0 L), respectively, and were independent of the dose level; mean half-life was 16.6 hours. Thus, erlotinib 125 mg/m2 per day has an acceptable tolerability profile in pediatric patients with brain tumors and can be combined with radiotherapy

Published
2011

39. Malformations, genetic abnormalities, and wilms tumor

Author

Dumoucel, S., primary, Gauthier-Villars, M., additional, Stoppa-Lyonnet, D., additional, Parisot, P., additional, Brisse, H., additional, Philippe-Chomette, P., additional, Sarnacki, S., additional, Boccon-Gibod, L., additional, Rossignol, S., additional, Baumann, C., additional, Aerts, I., additional, Bourdeaut, F., additional, Doz, F., additional, Orbach, D., additional, Pacquement, H., additional, Michon, J., additional, and Schleiermacher, G., additional

Published
2013
Full Text
View/download PDF

42. Commuter cycling in Flanders

Author

UCL - SSH/IACS - Institute of Analysis of Change in Contemporary and Historical Societies, de Geus, Bas, Joncheere, J., Aerts, I., Breynaert, J., Hellemans, S., Meeusen, Romain, UCL - SSH/IACS - Institute of Analysis of Change in Contemporary and Historical Societies, de Geus, Bas, Joncheere, J., Aerts, I., Breynaert, J., Hellemans, S., and Meeusen, Romain

Abstract

n/a

Published
2006

43. Pediatric uveal melanoma

Author

CASSOUX, N, primary, COUTURIER, J, additional, PLANCHER, C, additional, LUMBROSO-LE ROUIC, L, additional, LEVY, C, additional, ASSELAIN, B, additional, DENDALE, R, additional, AERTS, I, additional, and DESJARDINS, L, additional

Published
2012
Full Text
View/download PDF

44. 807 Experimental Therapeutic Approach of Orthotopic and Subcutaneous Human Retinoblastoma Xenografts by the Human Anti-VEGF Antibody Bevacizumab, Alone or in Combination With Carboplatin

Author

Decaudin, D., primary, Assayag, F., additional, Cassoux, N., additional, Chouchane-Mlik, O., additional, Némati, F, additional, Thuleau, A., additional, Aerts, I., additional, Doz, F., additional, Piperno-Neumann, S., additional, and Desjardins, L., additional

Published
2012
Full Text
View/download PDF

45. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Author

Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results